
  
    
      
        Background_NNP
        Since_IN the_DT initial_JJ report_NN by_IN Connolly_NNP ,_, et_CC al_NN [_NN 1_CD ]_NN of_IN
        valvulopathy_NN in_IN women_NNS taking_VBG the_DT combination_NN of_IN
        fenfluramine_NN and_CC phentermine_NN (_( fen-phen_JJ )_) ,_, controversy_NN has_VBZ
        surrounded_VBN the_DT issue_NN of_IN associated_VBN risk_NN ._. Initial_JJ reports_NNS of_IN
        remarkably_RB high_JJ prevalence_NN of_IN aortic_JJ and_CC mitral_NN
        regurgitation_NN (_( AR_NNP and_CC MR_NNP )_) as_IN assessed_VBN by_IN echocardiography_NN
        in_IN five_CD separate_JJ populations_NNS [_NN 2_CD ]_NN were_VBD subsequently_RB
        supported_VBN by_IN most_JJS [_NN 3_CD 4_CD 5_CD ]_NN but_CC not_RB all_DT investigators_NNS [_NN 6_CD ]_NN
        ._. These_DT uncontrolled_JJ reports_NNS were_VBD soon_RB followed_VBN by_IN a_DT series_NN
        of_IN studies_NNS in_IN which_WDT prevalence_NN of_IN
        echocardiographically-defined_JJ AR_NNP and_CC MR_NNP were_VBD assessed_VBN in_IN
        persons_NNS who_WP had_VBD taken_VBN fenfluramine_NN ,_, dexfenfluramine_NN ,_,
        phentermine_NN ,_, or_CC combinations_NNS of_IN these_DT medications_NNS and_CC
        compared_VBN to_TO unexposed_JJ ,_, matched_VBN control_NN populations_NNS [_NN 7_CD 8_CD 9_CD
        10_CD 11_CD 12_CD 13_CD 14_CD 15_CD ]_NN ._. The_DT most_RBS recent_JJ of_IN these_DT studies_NNS
        found_VBD 30_CD %_NN of_IN persons_NNS currently_RB taking_VBG fenfluramine_NN or_CC
        dexfenfluramine_NN had_VBD mild_JJ or_CC greater_JJR AR_NNP or_CC moderate_JJ or_CC
        greater_JJR MR_NNP ,_, similar_JJ to_TO the_DT very_RB high_JJ prevalence_NN reported_VBD in_IN
        older_JJR studies_NNS [_NN 15_CD ]_NN ._. The_DT only_RB prospective_JJ study_NN found_VBD a_DT
        significant_JJ ,_, exposure-related_JJ increase_NN in_IN the_DT risk_NN of_IN
        clinically_RB diagnosed_VBN valve_NN disease_NN among_IN users_NNS of_IN
        fenfluramine_NN and_CC dexfenfluramine_NN ,_, but_CC not_RB phentermine_NN [_NN 16_CD
        ]_NN ._.
        Some_DT recent_JJ reviews_NNS conclude_VBP that_IN the_DT risks_NNS associated_VBN
        with_IN fenfluramine_NN and_CC dexfenfluramine_NN are_VBP similar_JJ ,_, real_JJ but_CC
        modest_JJ for_IN aortic_JJ valve_NN disease_NN ,_, and_CC barely_RB detectable_JJ for_IN
        mitral_NN valve_NN disease_NN ;_: phentermine_NN appears_VBZ not_RB to_TO be_VB
        associated_VBN with_IN increased_VBN risk_NN [_NN 17_CD 18_CD 19_CD 20_CD ]_NN ._.
        Nevertheless_RB ,_, interpretation_NN of_IN the_DT results_NNS of_IN these_DT
        studies_NNS has_VBZ been_VBN so_RB varied_VBN that_IN some_DT authors_NNS have_VBP even_RB
        questioned_VBN any_DT causal_NN relationship_NN for_IN fenfluramine_NN
        exposure_NN [_NN 21_CD ]_NN ._. However_RB ,_, analyses_NNS to_TO date_NN have_VBP not_RB
        formally_RB considered_VBN major_JJ biases_NNS that_WDT would_MD act_VB to_TO deflate_VB
        the_DT actual_JJ risk_NN associated_VBN with_IN fenfluramine_NN use_NN ._. Most_JJS
        investigators_NNS have_VBP calculated_VBN only_RB prevalence_NN ratios_NNS or_CC
        prevalence_NN odds_NNS ratios_NNS ,_, dividing_VBG the_DT prevalence_NN or_CC odds_NNS of_IN
        valve_NN disease_NN in_IN exposed_VBN persons_NNS by_IN prevalence_NN or_CC odds_NNS in_IN
        an_DT unexposed_JJ control_NN group_NN ._. This_DT approach_NN contrasts_VBZ with_IN a_DT
        prospective_JJ design_NN wherein_WRB relative_JJ risk_NN is_VBZ calculated_VBN
        using_VBG only_RB newly_RB arising_VBG (_( incident_NN )_) cases_NNS and_CC with_IN
        conventional_JJ case-control_JJ studies_NNS in_IN which_WDT an_DT estimate_NN of_IN
        relative_JJ risk_NN (_( the_DT odds_NNS ratio_NN )_) can_MD be_VB made_VBN ._. If_IN persons_NNS with_IN
        prior_JJ valve_NN disease_NN are_VBP included_VBN in_IN both_DT the_DT exposed_VBN and_CC
        the_DT unexposed_JJ groups_NNS ,_, a_DT gross_JJ underestimate_NN of_IN actual_JJ risk_NN
        may_MD occur_VB ._. The_DT dilution_NN in_IN estimated_VBN risk_NN is_VBZ likely_JJ to_TO be_VB
        particularly_RB important_JJ if_IN the_DT background_NN prevalence_NN among_IN
        unexposed_JJ persons_NNS is_VBZ substantial_JJ but_CC the_DT incidence_NN of_IN new_JJ
        cases_NNS during_IN the_DT observation_NN period_NN is_VBZ small_JJ ,_, as_IN
        illustrated_VBN in_IN figure_NN 1_CD ._. While_IN other_JJ investigators_NNS have_VBP
        noted_VBN this_DT potentially_RB large_JJ bias_NN [_NN 22_CD ]_NN ,_, no_DT attempts_NNS at_IN
        appropriate_JJ correction_NN have_VBP been_VBN made_VBN ._.
        A_DT further_JJ source_NN of_IN under-estimated_JJ risk_NN in_IN prior_JJ
        studies_VBZ is_VBZ the_DT lack_NN of_IN consideration_NN given_VBN to_TO the_DT time_NN
        element_NN ._. In_IN a_DT typical_JJ prospective_JJ study_NN ,_, both_DT the_DT exposed_VBN
        and_CC unexposed_JJ groups_NNS are_VBP generally_RB followed_VBN for_IN an_DT equal_JJ
        period_NN of_IN time_NN ._. However_RB ,_, no_DT prior_RB echocardiographic_JJ study_NN
        examining_VBG anorexic_JJ drug-associated_JJ valve_NN disease_NN has_VBZ
        considered_VBN the_DT fact_NN that_IN measurable_JJ differences_NNS in_IN
        prevalence_NN have_VBP arisen_VBN among_IN persons_NNS exposed_VBN to_TO these_DT drugs_NNS
        over_IN a_DT remarkably_RB short_JJ period_NN of_IN time_NN (_( usually_RB a_DT few_JJ
        months_NNS )_) whereas_IN the_DT prevalent_JJ valve_NN disease_NN in_IN the_DT
        comparison_NN groups_NNS likely_RB arose_VBD over_IN a_DT number_NN of_IN years_NNS or_CC
        even_RB a_DT lifetime_NN ._.
        In_IN this_DT meta-analysis_JJ ,_, we_PRP estimated_VBD incidence_NN rates_NNS
        based_VBN on_IN duration_NN of_IN drug_NN exposure_NN and_CC compared_VBD these_DT to_TO
        expected_VB incidence_NN rates_NNS in_IN order_NN to_TO obtain_VB unbiased_JJ
        estimates_NNS of_IN relative_JJ risk_NN for_IN the_DT development_NN of_IN AR_NNP and_CC
        MR_NNP ._.
      
      
        Methods_NNP
        
          Study_NNP Search_NNP ,_, Selection_NN ,_, and_CC Data_NNP Extraction_NNP
          We_PRP first_RB sought_VBN to_TO identify_VB all_DT published_VBN studies_NNS with_IN
          echocardiographic_JJ assessment_NN of_IN cardiac_JJ valve_NN
          regurgitation_NN in_IN persons_NNS exposed_VBN to_TO fenfluramine_NN or_CC
          dexfenfluramine_NN and_CC in_IN suitable_JJ controls_NNS ._. The_DT search_NN for_IN
          studies_NNS included_VBD examination_NN of_IN prior_JJ meta-analyses_JJ and_CC
          reviews_NNS ,_, MEDLINE_NNP search_NN (_( using_VBG the_DT terms_NNS fenfluramine_NN or_CC
          dexfenfluramine_NN ,_, diet_NN drugs_NNS ,_, echocardiogram_NN or_CC
          echocardiographic_JJ ,_, and_CC valvular_NN heart_NN disease_NN )_) ,_, and_CC
          review_NN of_IN references_NNS of_IN identified_VBN articles_NNS ._. For_IN this_DT
          analysis_NN we_PRP included_VBD only_RB studies_VBZ that_WDT reported_JJ duration_NN
          of_IN medication_NN use_NN ._. In_IN some_DT studies_NNS ,_, results_NNS were_VBD reported_VBN
          separately_RB by_IN duration_NN of_IN exposure_NN ._. Each_DT duration_NN group_NN
          was_VBD considered_VBN as_IN a_DT separate_JJ observation_NN if_IN number_NN of_IN
          persons_NNS exposed_VBN ,_, number_NN of_IN cases_NNS observed_VBD ,_, and_CC duration_NN
          of_IN exposure_NN was_VBD reported_VBN ._.
        
        
          Data_NNP Synthesis_NNP
          We_PRP first_RB evaluated_VBN studies_NNS reporting_VBG echocardiographic_JJ
          prevalence_NN of_IN FDA-positive_NNP valvulopathy_NN (_( mild_JJ or_CC greater_JJR
          AR_NNP and_CC moderate_JJ or_CC greater_JJR MR_NNP )_) [_NN 2_CD ]_NN among_IN subjects_NNS who_WP
          had_VBD taken_VBN either_CC fenfluramine_NN or_CC dexfenfluramine_NN (_( alone_RB
          or_CC in_IN combination_NN with_IN phentermine_NN )_) and_CC in_IN matched_VBN
          controls_NNS [_NN 7_CD 8_CD 9_CD 10_CD 11_CD 12_CD 13_CD 14_CD ]_NN ._. In_IN most_JJS of_IN these_DT
          studies_NNS ,_, echocardiograms_NNS were_VBD performed_VBN after_IN the_DT drugs_NNS
          had_VBD been_VBN discontinued_VBN and_CC were_VBD read_VBN without_IN knowledge_NN of_IN
          prior_JJ drug_NN exposure_NN by_IN multiple_JJ readers_NNS (_( table_NN 1_LS )_) ._. In_IN
          some_DT studies_NNS ,_, control_NN subjects_NNS were_VBD derived_VBN from_IN patients_NNS
          assigned_VBN to_TO placebo_NN in_IN a_DT formal_JJ randomized_JJ trial_NN of_IN
          fenfluramine_NN or_CC dexfenfluramine_NN ._. In_IN others_NNS ,_, controls_NNS
          matched_VBN for_IN age_NN ,_, gender_NN and_CC BMI_NNP were_VBD recruited_VBN and_CC
          examined_VBN ._.
          In_IN a_DT true_JJ prospective_JJ study_NN ,_, persons_NNS with_IN valvulopathy_NN
          at_IN baseline_NN would_MD be_VB excluded_VBN from_IN follow-up_JJ or_CC
          calculation_NN of_IN incidence_NN rates_NNS ._. Since_IN only_RB one_CD study_NN had_VBD
          performed_VBN echocardiography_NN on_IN a_DT substantial_JJ number_NN of_IN
          subjects_NNS prior_RB to_TO initiation_NN of_IN the_DT diet_NN drugs_NNS [_NN 11_CD ]_NN ,_,
          some_DT means_NNS of_IN estimating_VBG and_CC correcting_VBG for_IN the_DT baseline_NN
          prevalence_NN in_IN the_DT other_JJ studies_NNS was_VBD necessary_JJ ._. For_IN this_DT
          analysis_NN we_PRP have_VBP used_VBN the_DT unexposed_JJ control_NN groups_NNS for_IN
          each_DT study_NN to_TO provide_VB such_PDT an_DT estimate_NN ._. Thus_RB ,_, the_DT
          prevalence_NN rate_NN in_IN the_DT control_NN (_( unexposed_JJ )_) group_NN of_IN each_DT
          study_NN was_VBD used_VBN to_TO estimate_VB the_DT number_NN of_IN background_NN cases_NNS
          expected_VBN in_IN the_DT exposed_VBN group_NN (_( s_VBZ )_) ._. Any_DT cases_NNS observed_VBD
          beyond_IN this_DT background_NN number_NN were_VBD considered_VBN "_'' new_JJ "_'' or_CC
          incident_NN cases_NNS ._. This_DT approach_NN is_VBZ mathematically_RB
          equivalent_JJ to_TO modelling_VBG the_DT rate_NN of_IN change_NN in_IN prevalence_NN
          in_IN the_DT exposed_VBN group_NN with_IN the_DT control_NN group_NN providing_VBG the_DT
          initial_JJ estimate_NN of_IN prevalence_NN ._. The_DT concept_NN is_VBZ
          illustrated_VBN in_IN figure_NN 2_CD using_VBG data_NNS from_IN Jollis_NNP ,_, et_CC al_NN [_NN 13_CD
          ]_NN ._. Duration_NNP of_IN drug_NN use_NN provided_VBD the_DT time_NN factor_NN to_TO
          estimate_VB incidence_NN in_IN the_DT exposed_VBN groups_NNS ._. Two_CD studies_NNS
          which_WDT did_VBD not_RB report_VB duration_NN of_IN drug_NN exposure_NN were_VBD
          therefore_RB excluded_VBN from_IN this_DT meta-analysis_JJ [_NN 15_CD 23_CD ]_NN
          ._.
          Of_IN major_JJ importance_NN in_IN this_DT analysis_NN is_VBZ the_DT estimation_NN
          of_IN the_DT expected_VBN incidence_NN rate_NN of_IN FDA-positive_NNP AR_NNP and_CC MR_NNP
          (_( for_IN estimation_NN of_IN relative_JJ risk_NN )_) ._. The_DT most_RBS
          straightforward_JJ estimate_NN of_IN incidence_NN would_MD require_VB a_DT
          sample_NN of_IN persons_NNS from_IN the_DT general_JJ population_NN having_VBG no_DT
          AR_NNP or_CC MR_NNP at_IN baseline_NN and_CC who_WP had_VBD a_DT repeat_NN echocardiogram_NN
          some_DT time_NN in_IN the_DT future_NN ._. While_IN two_CD studies_NNS performed_VBD
          echocardiograms_NNS one_CD year_NN apart_RB in_IN sizable_JJ populations_NNS ,_,
          both_DT showed_VBD either_CC no_DT net_JJ progression_NN or_CC a_DT net_JJ 
          decrease_NN in_IN regurgitation_NN in_IN the_DT
          unexposed_JJ ,_, control_NN groups_NNS [_NN 24_CD 25_CD ]_NN ._. These_DT findings_NNS
          underscore_VBP the_DT infrequency_NN of_IN new_JJ onset_NN ,_, FDA-positive_NNP AR_NNP
          or_CC MR_NNP in_IN the_DT unexposed_JJ population_NN ._.
          As_IN an_DT alternative_JJ estimate_NN of_IN expected_VBN incidence_NN we_PRP
          modelled_JJ change_NN in_IN prevalence_NN in_IN two_CD populations_NNS ._. In_IN the_DT
          first_JJ ,_, data_NNS from_IN the_DT Framingham_NNP study_NN were_VBD utilized_JJ [_NN 26_CD
          ]_NN ._. In_IN that_DT study_NN ,_, the_DT prevalence_NN of_IN FDA-positive_NNP AR_NNP or_CC
          MR_NNP in_IN persons_NNS under_IN age_NN 40_CD was_VBD zero_CD ._. The_DT prevalent_JJ cases_NNS
          in_IN the_DT following_VBG decade_NN (_( ages_NNS 40_CD -_: 49_CD )_) were_VBD therefore_RB
          assumed_VBN to_TO have_VB arisen_VBN since_IN age_NN 40_CD ._. For_IN each_DT subsequent_JJ
          decade_NN ,_, the_DT increase_NN in_IN prevalence_NN was_VBD assumed_VBN to_TO have_VB
          arisen_VBN since_IN the_DT prior_JJ decade_NN ._. Additional_JJ assumptions_NNS
          were_VBD that_IN incident_NN cases_NNS did_VBD not_RB drop_VB out_IN (_( that_WDT is_VBZ ,_, there_EX
          was_VBD no_DT differential_NN mortality_NN and_CC change_NN in_IN prevalence_NN
          was_VBD the_DT result_NN of_IN cumulative_JJ incidence_NN )_) ,_, that_IN incidence_NN
          rates_NNS were_VBD constant_JJ within_IN decades_NNS ,_, and_CC that_IN there_EX was_VBD no_DT
          cohort_NN effects_NNS (_( i_NNP ._. e_SYM ._. ,_, that_IN incidence_NN rates_NNS in_IN older_JJR
          individuals_NNS when_WRB they_PRP were_VBD young_JJ were_VBD similar_JJ to_TO the_DT
          incidence_NN rates_NNS in_IN currently_RB young_JJ individuals_NNS )_) ._. Given_VBN
          theses_NNS assumptions_NNS ,_, the_DT change_NN in_IN prevalence_NN is_VBZ given_VBN by_IN
          the_DT expression_NN
          1_LS -_: (_( 1_CD -_: i_NNP )_) t_NN
          were_VBD i_NNP is_VBZ the_DT incidence_NN rate_NN per_IN year_NN and_CC t_NN is_VBZ the_DT
          number_NN of_IN years_NNS between_IN prevalence_NN data_NNS points_NNS (_( 10_CD for_IN
          full_JJ decades_NNS )_) ._. The_DT equation_NN was_VBD solved_VBN for_IN i_NNP given_VBN the_DT
          observed_VBN change_NN in_IN prevalence_NN between_IN decades_NNS and_CC time_NN
          elapsed_VBN (_( using_VBG the_DT end_NN of_IN each_DT time_NN period_NN )_) ._. Incidence_NNP
          rates_NNS were_VBD calculated_VBN for_IN FDA-positive_NNP AR_NNP and_CC MR_NNP
          separately_RB for_IN each_DT decade_NN in_IN men_NNS and_CC women_NNS ._. These_DT
          estimated_VBN incidence_NN rates_NNS are_VBP shown_VBN in_IN table_NN 2_CD ._. As_IN a_DT
          conservative_JJ estimate_NN for_IN relative_JJ risk_NN calculations_NNS ,_, all_PDT
          the_DT rates_NNS were_VBD pooled_VBN (_( as_IN the_DT unweighted_JJ mean_NN of_IN the_DT
          calculated_VBN rates_NNS in_IN table_NN 2_CD for_IN men_NNS and_CC women_NNS )_) ,_,
          recognizing_VBG that_IN this_DT will_MD yield_VB a_DT higher_JJR "_'' unexposed_JJ "_''
          rate_NN than_IN was_VBD likely_JJ present_NN for_IN the_DT younger_JJR and_CC
          predominantly_RB female_JJ populations_NNS exposed_VBN to_TO the_DT anorexic_JJ
          drugs_NNS ._. The_DT average_JJ estimated_VBN Framingham_NNP incidence_NN rates_NNS
          for_IN age_NN 40_CD and_CC over_IN calculated_VBN in_IN this_DT manner_NN were_VBD 0_CD ._. 357_CD %_NN
          per_IN year_NN for_IN mild_JJ or_CC greater_JJR AR_NNP and_CC 0_CD ._. 143_CD %_NN per_IN year_NN for_IN
          moderate_JJ or_CC greater_JJR MR_NNP ._.
          The_DT second_JJ data_NN set_VBN used_VBN to_TO estimate_VB unexposed_JJ
          incidence_NN rates_NNS was_VBD the_DT control_NN groups_NNS of_IN the_DT studies_NNS
          listed_VBN in_IN table_NN 1_CD ._. Cases_NNS of_IN FDA-positive_NNP AR_NNP and_CC MR_NNP
          reported_VBD in_IN the_DT control_NN groups_NNS were_VBD assumed_VBN to_TO have_VB
          arisen_VBN between_IN age_NN 40_CD and_CC the_DT average_JJ age_NN of_IN the_DT control_NN
          group_NN in_IN each_DT study_NN ._. A_DT mean_NN of_IN the_DT estimated_VBN incidence_NN
          from_IN each_DT study_NN was_VBD calculated_VBN and_CC weighted_VBN by_IN the_DT number_NN
          of_IN controls_NNS per_IN study_NN ._. Since_IN FDA-positive_NNP AR_NNP and_CC MR_NNP are_VBP
          found_VBN in_IN other_JJ populations_NNS under_IN age_NN 40_CD [_NN 27_CD ]_NN ,_, the_DT
          assumption_NN that_IN all_PDT the_DT observed_VBD AR_NNP and_CC MR_NNP occurred_VBD only_RB
          after_IN age_NN 40_CD will_MD result_VB in_IN conservatively_RB high_JJ estimates_NNS
          of_IN incidence_NN (_( resulting_VBG in_IN lower_JJR estimates_NNS of_IN relative_JJ
          risk_NN )_) ._.
          The_DT observed_VBN number_NN of_IN "_'' incident_NN "_'' cases_NNS of_IN AR_NNP or_CC MR_NNP in_IN
          the_DT exposed_VBN group_NN was_VBD calculated_VBN as_IN the_DT total_JJ number_NN of_IN
          cases_NNS minus_CC the_DT number_NN expected_VBN at_IN baseline_NN (_( estimated_VBN
          from_IN the_DT prevalence_NN in_IN the_DT unexposed_JJ control_NN group_NN in_IN
          each_DT study_NN )_) ._. Any_DT negative_JJ numbers_NNS were_VBD set_VBN to_TO 0_CD (_( one_CD
          instance_NN of_IN AR_NNP with_IN under_IN 3_CD months_NNS exposure_NN )_) ._. The_DT
          expected_VBN number_NN of_IN cases_NNS in_IN the_DT exposed_VBN population_NN (_( for_IN
          Poisson_NNP analyses_NNS )_) was_VBD calculated_VBN as_IN the_DT incidence_NN rate_NN
          (_( per_IN year_NN )_) determined_VBN from_IN the_DT pooled_VBN rate_NN in_IN controls_NNS
          (_( obtained_VBN as_IN described_VBN above_IN )_) multiplied_VBN by_IN the_DT duration_NN
          of_IN exposure_NN (_( in_IN years_NNS )_) ._. The_DT probability_NN of_IN observing_VBG the_DT
          number_NN of_IN "_'' incident_NN "_'' cases_NNS in_IN the_DT exposed_VBN group_NN of_IN each_DT
          individual_JJ study_NN given_VBN the_DT number_NN expected_VBN from_IN the_DT
          pooled_VBN estimate_NN was_VBD calculated_VBN using_VBG a_DT Poisson_NNP
          distribution_NN ._. Confidence_NN intervals_NNS for_IN the_DT percent_NN of_IN
          incident_NN cases_NNS during_IN each_DT study_NN (_( figures_NNS 3_CD and_CC 4_LS )_) were_VBD
          calculated_VBN as_IN suggested_VBN by_IN Fleiss_NNP for_IN observed_VBD versus_CC
          expected_VBN proportions_NNS [_NN 28_CD ]_NN ._. Effect_NN of_IN exposure_NN duration_NN
          and_CC other_JJ factors_NNS on_IN percent_NN of_IN incident_NN cases_NNS during_IN
          each_DT study_NN was_VBD tested_VBN in_IN a_DT weighted_JJ analysis_NN of_IN
          covariance_NN using_VBG the_DT GLM_NNP procedure_NN in_IN SAS_NNP (_( SAS_NNP Institute_NNP ,_,
          Carey_NNP ,_, North_NNP Carolina_NNP )_) ._.
          Relative_NNP risks_NNS were_VBD calculated_VBN as_IN (_( incident_NN cases_NNS /_NN
          person-years_JJ in_IN exposed_VBN )_) /_NN (_( cases_NNS in_IN controls_NNS /_NN
          person-years_JJ in_IN controls_NNS )_) ._. Person-years_NNP in_IN the_DT exposed_VBN
          group_NN were_VBD calculated_VBN as_IN :_: (_( total_JJ number_NN exposed_VBN -_: cases_NNS
          expected_VBN at_IN baseline_NN )_) ×_NN (_( mean_VB duration_NN of_IN drug_NN use_NN
          reported_VBD for_IN each_DT study_NN )_) ._. Person-years_NNP in_IN unexposed_JJ
          controls_NNS were_VBD calculated_VBN as_IN :_: (_( total_JJ number_NN in_IN the_DT control_NN
          group_NN )_) ×_NN (_( the_DT number_NN of_IN years_NNS from_IN age_NN 40_CD to_TO the_DT average_JJ
          age_NN of_IN the_DT group_NN )_) ._. Note_VB that_WDT pooled_VBN incidence_NN rates_NNS for_IN
          the_DT unexposed_JJ were_VBD not_RB used_VBN in_IN this_DT analysis_NN (_( so_RB as_RB not_RB
          to_TO inflate_VB power_NN )_) ;_: rather_RB ,_, each_DT study_NN provided_VBD its_PRP$ own_JJ
          estimates_NNS ._. Significance_NN and_CC confidence_NN intervals_NNS for_IN the_DT
          relative_JJ risks_NNS were_VBD calculated_VBN as_IN suggested_VBN by_IN Kleinbaum_NNP ,_,
          et_CC al_NN [_NN 29_CD ]_NN for_IN a_DT density_NN type_NN follow-up_JJ study_NN ._. This_DT
          approach_NN tests_VBZ the_DT difference_NN in_IN incidence_NN between_IN two_CD
          groups_NNS given_VBN that_IN follow-up_JJ time_NN may_MD be_VB different_JJ in_IN the_DT
          exposed_VBN and_CC unexposed_JJ populations_NNS ._.
        
      
      
        Results_NNS
        Raw_NNP data_NNS from_IN each_DT study_NN is_VBZ given_VBN for_IN mild_JJ or_CC greater_JJR AR_NNP
        in_IN table_NN 3_CD and_CC for_IN moderate_JJ or_CC greater_JJR MR_NNP in_IN table_NN 4_CD ._.
        Estimates_NNS of_IN unexposed_JJ incidence_NN of_IN AR_NNP and_CC MR_NNP utilizing_VBG
        data_NNS from_IN the_DT control_NN groups_NNS in_IN these_DT studies_NNS yielded_VBD
        values_NNS approximately_RB 50_CD %_NN higher_JJR than_IN estimates_NNS from_IN the_DT
        Framingham_NNP study_NN ;_: 0_CD ._. 555_CD %_NN per_IN year_NN for_IN mild_JJ or_CC greater_JJR AR_NNP
        and_CC 0_CD ._. 219_CD %_NN per_IN year_NN for_IN moderate_JJ or_CC greater_JJR MR_NNP ._. To_TO provide_VB
        conservative_JJ estimates_NNS of_IN relative_JJ risk_NN ,_, these_DT rates_NNS were_VBD
        used_VBN to_TO calculate_VB the_DT expected_VBN number_NN affected_VBN (_( given_VBN the_DT
        duration_NN of_IN exposure_NN in_IN each_DT study_NN )_) for_IN Poisson_NNP analyses_NNS in_IN
        tables_NNS 5_CD and_CC 6_CD ._. Estimates_NNS of_IN "_'' incident_NN "_'' cases_NNS and_CC relative_JJ
        risks_NNS based_VBN on_IN person-years_JJ are_VBP also_RB given_VBN in_IN tables_NNS 5_CD and_CC
        6_CD ._.
        The_DT percent_NN of_IN incident_NN cases_NNS of_IN AR_NNP during_IN each_DT study_NN
        (_( calculated_VBN without_IN dividing_VBG by_IN duration_NN of_IN exposure_NN for_IN
        this_DT analysis_NN )_) was_VBD found_VBN to_TO be_VB clearly_RB related_VBN to_TO duration_NN
        of_IN exposure_NN ._. This_DT is_VBZ illustrated_VBN in_IN figure_NN 3_CD ._. In_IN a_DT weighted_JJ
        analysis_NN of_IN covariance_NN including_VBG all_PDT the_DT studies_NNS in_IN table_NN
        5_CD ,_, R_NN 2_CD was_VBD 0_CD ._. 75_CD ,_, suggesting_VBG that_IN 75_CD %_NN of_IN the_DT variance_NN between_IN
        the_DT studies_NNS of_IN the_DT percent_NN of_IN incident_NN cases_NNS was_VBD explained_VBN
        by_IN duration_NN of_IN exposure_NN ._. The_DT coefficient_NN relating_VBG estimated_VBN
        incidence_NN to_TO duration_NN (_( in_IN months_NNS )_) was_VBD 0_CD ._. 00720_CD (_( p_NN <_NN
        0_CD ._. 0001_CD )_) ._. In_IN contrast_NN ,_, time_NN since_IN stopping_VBG drug_NN and_CC dose_NN
        were_VBD not_RB related_VBN to_TO estimated_VBN incidence_NN in_IN this_DT analysis_NN ._.
        All_DT but_CC three_CD of_IN the_DT 95_CD %_NN confidence_NN intervals_NNS from_IN these_DT 22_CD
        point_NN estimates_NNS included_VBD the_DT regression_NN line_NN ,_, suggesting_VBG a_DT
        fairly_RB homogeneous_JJ estimate_NN of_IN risk_NN ._. Remarkably_NNP ,_, the_DT
        predicted_VBD cumulative_JJ incidence_NN after_IN 1_CD year_NN exposure_NN was_VBD
        9_CD ._. 6_CD %_NN ._. The_DT weighted_JJ estimate_NN of_IN incidence_NN from_IN all_DT studies_NNS
        combined_VBN (_( ignoring_VBG duration_NN of_IN exposure_NN )_) was_VBD 6_CD ._. 29_CD %_NN (_( 95_CD %_NN CI_NNP
        5_CD ._. 51_CD %_NN -_: 7_CD ._. 16_CD %_NN ,_, z_SYM =_SYM 14_CD ._. 2_LS ,_, p_NN <_NN 0_CD ._. 00001_CD )_) during_IN a_DT mean_JJ
        exposure_NN time_NN of_IN 8_CD ._. 78_CD months_NNS ._. This_DT contrasts_VBZ with_IN an_DT
        expected_VBN incidence_NN of_IN 0_CD ._. 42_CD %_NN in_IN 9_CD months_NNS at_IN the_DT rate_NN
        estimated_VBN from_IN the_DT pooled_VBN control_NN groups_NNS of_IN these_DT studies_NNS ._.
        The_DT summary_NN relative_JJ risk_NN for_IN AR_NNP was_VBD 19_CD ._. 6_CD (_( 95_CD %_NN CI_NNP 16_CD ._. 3_LS -_:
        23_CD ._. 5_LS ,_, p_NN <_NN 0_CD ._. 00001_CD )_) ._.
        The_DT percent_NN of_IN incidence_NN cases_NNS of_IN moderate_JJ or_CC greater_JJR MR_NNP
        was_VBD lower_JJR than_IN AR_NNP in_IN these_DT studies_NNS ._. There_EX was_VBD no_DT
        significant_JJ correlation_NN with_IN duration_NN of_IN exposure_NN (_( R_NN 2_CD =_SYM
        0_CD ._. 126_CD ,_, regression_NN coefficient_NN =_SYM 0_CD ._. 00037_CD ,_, p_NN =_SYM 0_CD ._. 39_CD )_) or_CC with_IN
        dose_NN or_CC time_NN since_IN stopping_VBG drug_NN (_( by_IN weighted_JJ analysis_NN of_IN
        covariance_NN using_VBG continuous_JJ variables_NNS )_) ._. The_DT percent_NN of_IN
        incidence_NN cases_NNS was_VBD marginally_RB greater_JJR in_IN those_DT exposed_VBN for_IN
        3_CD months_NNS or_CC more_JJR (_( 1_CD ._. 30_CD %_NN ±_NN 0_CD ._. 19_CD ,_, mean_VBP ±_NN SE_NNP )_) compared_VBN to_TO
        those_DT with_IN lower_JJR exposure_NN times_NNS (_( 0_CD ._. 54_CD %_NN ±_NN 0_CD ._. 31_CD ,_, p_NN =_SYM 0_CD ._. 09_CD )_) ._.
        Overall_RB ,_, estimated_VBN incidence_NN was_VBD markedly_RB greater_JJR than_IN
        expected_VBN in_IN most_JJS studies_NNS as_IN shown_VBN in_IN figure_NN 4_CD and_CC table_NN 6_CD ._.
        The_DT weighted_JJ estimate_NN of_IN incidence_NN of_IN MR_NNP including_VBG all_DT
        studies_NNS was_VBD 1_CD ._. 09_CD %_NN (_( 95_CD %_NN CI_NNP 0_CD ._. 78_CD %_NN -_: 1_CD ._. 50_CD %_NN ,_, z_SYM =_SYM 5_CD ._. 2_CD ,_, p_NN <_NN
        0_CD ._. 00001_CD )_) during_IN an_DT average_JJ exposure_NN time_NN of_IN 8_CD ._. 89_CD months_NNS
        with_IN an_DT expected_VBN incidence_NN of_IN 0_CD ._. 16_CD %_NN in_IN 9_CD months_NNS based_VBN on_IN
        the_DT pooled_VBN control_NN groups_NNS ._. The_DT summary_NN relative_JJ risk_NN for_IN MR_NNP
        was_VBD 5_CD ._. 9_CD (_( 95_CD %_NN CI_NNP 4_CD ._. 0_CD -_: 8_CD ._. 6_CD ,_, p_NN <_NN 0_CD ._. 00001_CD )_) ._.
      
      
        Discussion_NNP
        Prior_RB summary_NN estimates_NNS of_IN risk_NN for_IN developing_VBG
        FDA-positive_NNP AR_NNP and_CC MR_NNP have_VBP been_VBN based_VBN on_IN simple_JJ
        comparisons_NNS of_IN prevalence_NN in_IN persons_NNS exposed_VBN and_CC unexposed_JJ
        to_TO anorexic_JJ drugs_NNS ._. For_IN example_NN ,_, without_IN making_VBG any_DT
        adjustments_NNS to_TO observed_VBD prevalence_NN rates_NNS ,_, Loke_NNP ,_, et_CC al_NN [_NN 18_CD
        ]_NN reported_VBD a_DT summary_NN "_'' relative_JJ risk_NN "_'' of_IN 2_CD ._. 82_CD (_( 95_CD %_NN CI_NNP 2_CD ._. 20_CD -_:
        3_CD ._. 61_CD ,_, z_SYM =_SYM 8_CD ._. 21_CD ,_, p_NN <_NN 0_CD ._. 0001_CD )_) for_IN FDA-positive_NNP AR_NNP and_CC 1_CD ._. 55_CD
        (_( 95_CD %_NN CI_NNP 1_CD ._. 06_CD -_: 2_CD ._. 25_CD ,_, z_SYM =_SYM 2_CD ._. 28_CD ,_, p_NN =_SYM 0_CD ._. 02_CD )_) for_IN MR_NNP utilizing_VBG
        most_JJS of_IN the_DT same_JJ studies_NNS included_VBN in_IN the_DT present_JJ report_NN ._.
        Our_PRP$ findings_NNS suggest_VBP that_IN these_DT estimates_NNS are_VBP strongly_RB
        biased_VBN toward_IN the_DT null_NN because_IN of_IN counting_VBG background_NN ,_,
        prevalent_JJ cases_NNS as_IN incident_NN cases_NNS in_IN both_DT exposed_VBN and_CC
        unexposed_JJ groups_NNS (_( a_DT form_NN of_IN nondifferential_NN
        misclassification_NN )_) and_CC not_RB considering_VBG the_DT remarkably_RB short_JJ
        period_NN of_IN exposure_NN during_IN which_WDT most_JJS observed_VBN differences_NNS
        in_IN prevalence_NN arose_VBD ._. In_IN contrast_NN ,_, we_PRP found_VBD much_RB higher_JJR
        relative_JJ risks_NNS using_VBG methods_NNS to_TO correct_VB for_IN these_DT biases_NNS ;_:
        19_CD ._. 6_CD for_IN AR_NNP and_CC 5_CD ._. 9_CD for_IN MR_NNP (_( both_DT p_NN <_NN 0_CD ._. 00001_CD )_) ._.
        Furthermore_RB ,_, our_PRP$ estimates_NNS of_IN percent_NN incident_NN cases_NNS of_IN AR_NNP
        among_IN exposed_VBN were_VBD highly_RB correlated_JJ with_IN duration_NN of_IN
        exposure_NN and_CC appeared_VBD homogeneous_JJ ,_, suggesting_VBG a_DT
        biologically_RB relevant_JJ ,_, strong_JJ ,_, causal_NN relationship_NN ._.
        Are_VBP these_DT high_JJ estimates_NNS of_IN risk_NN unprecedented_JJ ?_. In_IN the_DT
        only_RB true_JJ prospective_JJ study_NN comparing_VBG risk_NN in_IN exposed_VBN and_CC
        unexposed_JJ persons_NNS ,_, Jick_NNP ,_, et_CC al_NN [_NN 16_CD ]_NN identified_VBN clinically_RB
        diagnosed_VBN valvular_NN disease_NN using_VBG the_DT large_JJ UK_NNP General_NNP
        Practice_NNP Research_NNP Database_NNP ._. Using_VBG the_DT data_NNS provided_VBN in_IN the_DT
        paper_NN ,_, a_DT valve-specific_JJ analysis_NN may_MD be_VB performed_VBN comparing_VBG
        incidence_NN of_IN aortic_JJ and_CC mitral_NN disease_NN in_IN those_DT exposed_VBN for_IN
        4_CD months_NNS or_CC longer_RBR versus_CC all_DT others_NNS ._. The_DT results_NNS reveal_VBP a_DT
        relative_JJ risk_NN of_IN 17_CD ._. 1_LS for_IN AR_NNP and_CC 34_CD ._. 3_LS for_IN MR_NNP ,_, both_DT with_IN p_NN
        <_NN 0_CD ._. 0001_CD by_IN chi-square_JJ ._. Since_IN the_DT few_JJ cases_NNS that_WDT arose_VBD
        within_IN 3_CD months_NNS of_IN exposure_NN are_VBP included_VBN in_IN the_DT "_'' unexposed_JJ "_''
        group_NN in_IN this_DT analysis_NN ,_, even_RB these_DT high_JJ risks_NNS represent_VBP an_DT
        underestimate_NN ._. Nevertheless_RB ,_, the_DT close_JJ similarity_NN in_IN the_DT
        estimate_NN of_IN AR_NNP relative_JJ risk_NN to_TO the_DT present_JJ study_NN is_VBZ
        remarkable_JJ ._. The_DT much_RB higher_JJR risk_NN for_IN MR_NNP compared_VBD to_TO our_PRP$
        estimate_NN may_MD represent_VB fundamental_JJ biological_JJ differences_NNS
        between_IN clinically_RB apparent_JJ valve_NN disease_NN and_CC
        echocardiographically_RB assessed_VBN valve_NN disease_NN ._.
        A_DT single_JJ study_NN among_IN those_DT reviewed_VBN in_IN our_PRP$ meta-analysis_JJ
        excluded_VBN persons_NNS with_IN valve_NN disease_NN using_VBG echocardiograms_NNS
        taken_VBN prior_RB to_TO starting_VBG drug_NN [_NN 11_CD ]_NN ._. That_DT study_NN yielded_VBD
        estimates_NNS of_IN AR_NNP and_CC MR_NNP incidence_NN that_WDT were_VBD similar_JJ to_TO our_PRP$
        summary_NN estimates_NNS ,_, further_JJ supporting_VBG our_PRP$ findings_NNS ._. The_DT
        fact_NN that_IN so_RB many_JJ studies_NNS have_VBP observed_VBN statistically_RB
        significant_JJ differences_NNS in_IN prevalence_NN after_IN relatively_RB
        short_JJ exposure_NN to_TO drug_NN suggest_VBP that_IN underlying_VBG incidence_NN
        rates_NNS of_IN new_JJ valvulopathy_NN must_MD be_VB extraordinarily_RB high_JJ
        compared_VBN to_TO the_DT expected_VBN low_JJ unexposed_JJ rate_NN ._.
        Data_NNP provided_VBD in_IN this_DT study_NN can_MD be_VB used_VBN to_TO estimate_VB the_DT
        relative_JJ contribution_NN of_IN exposure_NN to_TO fenfluramines_NNS to_TO
        overall_JJ incidence_NN of_IN echocardiographically_RB defined_VBN ,_,
        FDA-positive_NNP AR_NNP and_CC MR_NNP ._. Given_VBN that_IN approximately_RB 2_CD ._. 5_CD %_NN of_IN
        the_DT population_NN of_IN the_DT United_NNP States_NNPS had_VBD used_VBN anorexic_JJ
        prescription_NN drugs_NNS (_( mostly_RB fenfluramine_NN and_CC
        dexfenfluramine_NN )_) between_IN 1996_CD and_CC 1998_CD [_NN 30_CD ]_NN ,_,
        approximately_RB 32_CD %_NN and_CC 11_CD %_NN of_IN all_DT FDA-positive_NNP AR_NNP and_CC MR_NNP
        respectively_RB could_MD be_VB attributed_VBN to_TO fenfluramine_NN or_CC
        dexfenfluramine_NN use_NN ._. Among_IN those_DT who_WP had_VBD actually_RB taken_VBN the_DT
        drugs_NNS ,_, the_DT attributable_JJ fraction_NN rises_VBZ to_TO 95_CD %_NN and_CC 83_CD %_NN for_IN
        AR_NNP and_CC MR_NNP respectively_RB ._.
        Why_WRB was_VBD there_EX no_DT apparent_JJ effect_NN of_IN exposure_NN duration_NN on_IN
        MR_NNP incidence_NN ?_. This_DT may_MD well_RB be_VB due_JJ to_TO low_JJ power_NN ._. If_IN only_RB
        0_CD ._. 25_CD of_IN an_DT incident_NN case_NN had_VBD been_VBN seen_VBN in_IN the_DT exposed_VBN group_NN
        of_IN Hensrud_NNP ,_, et_CC al_NN [_NN 10_CD ]_NN and_CC 1_CD extra_JJ case_NN had_VBD been_VBN seen_VBN in_IN
        the_DT group_NN exposed_VBD 30_CD months_NNS in_IN Jollis_NNP ,_, et_CC al_NN [_NN 13_CD ]_NN then_RB a_DT
        significant_JJ logarithmic_JJ relationship_NN between_IN duration_NN and_CC
        percent_NN incident_NN cases_NNS would_MD have_VB become_VBN apparent_JJ ,_,
        illustrating_VBG the_DT precarious_JJ nature_NN of_IN correlations_NNS when_WRB
        events_NNS are_VBP few_JJ ._. While_IN we_PRP cannot_NN claim_NN such_JJ a_DT relationship_NN
        does_VBZ exist_VB ,_, the_DT relatively_RB low_JJ incidence_NN seen_VBN generally_RB for_IN
        moderate_JJ or_CC greater_JJR MR_NNP makes_VBZ establishing_VBG strong_JJ
        correlations_NNS difficult_JJ ._. Importantly_NNP ,_, we_PRP cannot_NN conclude_VB
        that_IN a_DT positive_JJ association_NN between_IN exposure_NN duration_NN and_CC
        incident_NN MR_NNP does_VBZ 
        not_RB exist_VB ,_, only_RB that_IN the_DT current_JJ
        studies_NNS are_VBP inconclusive_JJ regarding_VBG this_DT relationship_NN ._. We_PRP
        can_MD conclude_VB ,_, however_RB that_IN the_DT current_JJ studies_NNS provide_VBP
        sufficient_JJ power_NN in_IN aggregate_JJ to_TO clearly_RB demonstrate_VB an_DT
        overall_JJ excess_JJ risk_NN for_IN developing_VBG MR_NNP ._.
        Another_DT approach_NN to_TO expressing_VBG excess_JJ risk_NN is_VBZ the_DT
        calculation_NN of_IN "_'' number_NN needed_VBN to_TO harm_VB "_'' (_( NNH_NNP )_) ._. NNH_NNP may_MD be_VB
        calculated_VBN as_IN the_DT inverse_NN of_IN the_DT difference_NN between_IN risk_NN in_IN
        exposed_VBN and_CC risk_NN in_IN unexposed_JJ persons_NNS ._. For_IN example_NN ,_, the_DT
        cumulative_JJ prevalence_NN of_IN AR_NNP was_VBD 95_CD ._. 6_CD per_IN 1000_CD in_IN those_DT
        exposed_VBN to_TO fenfluramines_NNS without_IN regard_NN to_TO exposure_NN time_NN
        (_( 342_CD cases_NNS among_IN 3576_CD exposed_VBN ,_, from_IN table_NN 3_LS )_) compared_VBN to_TO
        34_CD ._. 7_CD per_IN thousand_CD among_IN unexposed_JJ (_( 77_CD cases_NNS among_IN 2222_CD
        unexposed_JJ )_) for_IN a_DT NNH_NNP of_IN 16_CD ._. 4_LS ._. For_IN MR_NNP ,_, the_DT cumulative_JJ
        prevalence_NN was_VBD 29_CD ._. 9_CD per_IN 1000_CD in_IN exposed_VBN (_( 107_CD of_IN 3582_CD
        exposed_VBN ,_, from_IN table_NN 4_LS )_) versus_CC 19_CD ._. 8_CD per_IN thousand_CD (_( 34_CD of_IN 2225_CD
        exposed_VBN )_) for_IN a_DT NNH_NNP of_IN 99_CD ._. A_DT risk_NN difference_NN ,_, as_IN used_VBN to_TO
        calculate_VB NNH_NNP ,_, is_VBZ less_RBR subject_JJ to_TO nondifferential_NN
        misclassification_NN than_IN is_VBZ a_DT risk_NN ratio_NN ._. However_RB ,_,
        demonstrating_VBG association_NN with_IN graded_JJ exposures_NNS and_CC
        statistical_JJ methods_NNS to_TO determine_VB significance_NN or_CC confidence_NN
        intervals_NNS are_VBP well_RB defined_VBN for_IN relative_JJ risk_NN but_CC not_RB for_IN
        NNH_NNP ._. We_PRP have_VBP therefore_RB emphasized_VBN estimates_NNS of_IN relative_JJ
        risk_NN ._. Importantly_NNP ,_, estimates_VBZ of_IN NNH_NNP as_IN calculated_VBN by_IN
        differences_NNS between_IN exposed_VBN and_CC unexposed_JJ prevalence_NN rates_NNS ,_,
        shown_VBN above_IN ,_, were_VBD very_RB similar_JJ to_TO NNH_NNP determined_VBD using_VBG
        differences_NNS between_IN our_PRP$ estimated_VBN 9_CD -_: month_NN incidence_NN rates_NNS
        in_IN exposed_VBN and_CC unexposed_JJ (_( NNH_NNP was_VBD 17_CD for_IN AR_NNP and_CC 108_CD for_IN MR_NNP
        by_IN this_DT approach_NN )_) ,_, further_JJ illustrating_VBG the_DT internal_JJ
        consistency_NN of_IN our_PRP$ analysis_NN ._.
        Our_PRP$ study_NN has_VBZ several_JJ limitations_NNS ._. There_EX is_VBZ no_DT direct_JJ
        measure_NN of_IN true_JJ incidence_NN of_IN AR_NNP or_CC MR_NNP in_IN the_DT unexposed_JJ
        population_NN ._. The_DT only_JJ studies_VBZ to_TO perform_VB repeated_VBN
        echocardiograms_NNS (_( separated_VBN by_IN one_CD year_NN in_IN both_DT )_) in_IN large_JJ
        numbers_NNS of_IN unexposed_JJ persons_NNS found_VBD either_CC no_DT net_JJ
        progression_NN or_CC net_JJ regression_NN in_IN their_PRP$ control_NN groups_NNS [_NN 24_CD
        25_CD ]_NN ._. Because_IN these_DT studies_NNS did_VBD not_RB report_VB usable_JJ direct_JJ
        measures_NNS of_IN incidence_NN ,_, we_PRP made_VBD several_JJ assumptions_NNS to_TO
        estimate_VB unexposed_JJ incidence_NN using_VBG raw_JJ data_NNS from_IN the_DT
        Framingham_NNP study_NN and_CC from_IN the_DT studies_NNS reviewed_VBN here_RB ._. Our_PRP$
        observation_NN that_IN incidence_NN rates_NNS estimated_VBD from_IN both_DT
        populations_NNS were_VBD of_IN a_DT similar_JJ magnitude_NN supports_VBZ the_DT
        feasibility_NN of_IN this_DT approach_NN ._. Further_RB ,_, our_PRP$ estimate_NN is_VBZ
        conservative_JJ ._. For_IN example_NN ,_, using_VBG the_DT Framingham_NNP estimates_NNS
        would_MD have_VB yielded_VBN 50_CD %_NN higher_JJR relative_JJ risks_NNS ._. Had_VBD we_PRP
        subtracted_VBD the_DT prevalence_NN of_IN FDA-positive_NNP AR_NNP (_( 1_CD ._. 2_LS %_NN )_) and_CC MR_NNP
        (_( 1_CD ._. 0_CD %_NN )_) seen_VBN in_IN the_DT CARDIA_NNP study_NN [_NN 27_CD ]_NN and_CC considered_VBD the_DT
        time_NN course_NN of_IN new_JJ valve_NN disease_NN development_NN to_TO commence_NN at_IN
        age_NN 35_CD (_( the_DT ending_VBG age_NN of_IN the_DT CARDIA_NNP study_NN )_) ,_, the_DT unexposed_JJ
        incidence_NN would_MD have_VB been_VBN approximately_RB half_PDT the_DT rate_NN we_PRP
        used_VBD and_CC the_DT relative_JJ risks_NNS doubled_VBD ._.
        Our_PRP$ estimate_NN of_IN apparent_JJ incidence_NN of_IN AR_NNP and_CC MR_NNP among_IN
        the_DT exposed_VBN groups_NNS is_VBZ also_RB based_VBN on_IN several_JJ assumptions_NNS ._.
        However_RB ,_, the_DT strong_JJ ,_, consistent_JJ relationship_NN between_IN the_DT
        percent_NN of_IN incident_NN cases_NNS of_IN AR_NNP in_IN each_DT study_NN and_CC duration_NN
        of_IN exposure_NN suggests_VBZ that_IN our_PRP$ estimates_NNS were_VBD reasonable_JJ and_CC
        biologically_RB relevant_JJ ._. We_PRP acknowledge_VBP that_IN there_EX were_VBD a_DT
        number_NN of_IN differences_NNS between_IN the_DT study_NN groups_NNS included_VBN in_IN
        our_PRP$ analysis_NN ._. There_EX were_VBD differences_NNS in_IN study_NN design_NN and_CC
        methods_NNS (_( though_IN most_JJS were_VBD quite_RB similar_JJ )_) ,_, fenfluramine_NN or_CC
        dexfenfluramine_NN doses_NNS (_( though_IN in_IN most_JJS studies_NNS ,_, doses_NNS were_VBD
        similar_JJ )_) ,_, additional_JJ drugs_NNS used_VBN ,_, patient_NN characteristics_NNS ,_,
        interval_NN between_IN cessation_NN of_IN therapy_NN and_CC echocardiography_NN ,_,
        and_CC completeness_NN of_IN follow-up_JJ ._. However_RB ,_, these_DT differences_NNS
        would_MD likely_RB add_VB random_JJ error_NN and_CC therefore_RB 
        decrease_VB any_DT observed_VBN correlation_NN ._.
        Estimates_NNS of_IN incidence_NN among_IN unexposed_JJ controls_NNS from_IN each_DT
        study_NN were_VBD more_RBR variable_JJ ,_, resulting_VBG in_IN greater_JJR differences_NNS
        between_IN studies_NNS in_IN estimates_NNS of_IN relative_JJ risk_NN ._. This_DT is_VBZ not_RB
        surprising_VBG considering_VBG the_DT relatively_RB rare_JJ occurrence_NN of_IN
        new_JJ onset_NN AR_NNP or_CC MR_NNP in_IN unexposed_JJ middle-aged_JJ men_NNS and_CC
        women_NNS ._.
        We_PRP have_VBP not_RB formally_RB considered_VBN other_JJ potential_JJ sources_NNS
        of_IN bias_NN in_IN our_PRP$ analyses_NNS ._. These_DT include_VBP measurement_NN bias_NN
        (_( related_VBN to_TO acquisition_NN and_CC reading_NN of_IN echocardiograms_NNS )_) [_NN
        22_CD ]_NN ,_, selection_NN bias_NN (_( particularly_RB in_IN studies_NNS with_IN
        incomplete_JJ follow-up_JJ )_) [_NN 31_CD ]_NN ,_, and_CC potential_JJ reversibility_NN
        of_IN valvulopathy_NN [_NN 10_CD 24_CD 25_CD 32_CD ]_NN ._. If_IN a_DT reversible_JJ component_NN
        occurred_VBD rather_RB quickly_RB after_IN stopping_VBG drugs_NNS ,_, then_RB one_PRP
        might_MD expect_VB a_DT stable_NN ,_, lower_JJR prevalence_NN in_IN studies_NNS
        performed_VBN well_RB after_IN drugs_NNS were_VBD stopped_VBN ,_, with_IN no_DT
        relationship_NN between_IN prevalence_NN of_IN valve_NN dysfunction_NN and_CC
        time_NN off_IN medication_NN ._. Indeed_RB ,_, the_DT most_RBS recently_RB published_VBN
        study_NN (_( which_WDT did_VBD not_RB suffer_VB from_IN measurement_NN bias_NN )_) showed_VBD a_DT
        high_JJ prevalence_NN (_( 30_CD %_NN )_) of_IN AR_NNP in_IN persons_NNS taking_VBG fenfluramine_NN
        or_CC dexfenfluramine_NN at_IN the_DT time_NN of_IN the_DT echocardiogram_NN ,_,
        similar_JJ to_TO the_DT older_JJR prevalence_NN studies_NNS [_NN 15_CD ]_NN ._. Regarding_VBG
        the_DT potential_JJ reversibility_NN of_IN valve_NN dysfunction_NN ,_, great_JJ
        caution_NN must_MD be_VB exercised_VBN in_IN assuming_VBG any_DT substantial_JJ
        reversal_NN of_IN valvular_NN plaques_NNS ,_, as_IN recent_JJ pathological_JJ
        studies_NNS suggest_VBP a_DT progressive_JJ nature_NN to_TO these_DT lesions_NNS [_NN 33_CD
        ]_NN ._. Furthermore_RB ,_, limited_JJ ,_, early_JJ apparent_JJ echocardiographic_JJ
        improvement_NN of_IN acute_JJ rheumatic_JJ carditis_NNS has_VBZ also_RB been_VBN
        recently_RB demonstrated_VBN [_NN 34_CD ]_NN ._. The_DT early_JJ improvement_NN seen_VBN
        in_IN this_DT setting_VBG certainly_RB does_VBZ not_RB preclude_VB later_RB
        progression_NN of_IN rheumatic_JJ valvular_NN heart_NN disease_NN ._.
        In_IN conclusion_NN ,_, we_PRP have_VBP estimated_VBN risks_NNS associated_VBN with_IN
        use_NN of_IN fenfluramine_NN or_CC dexfenfluramine_NN for_IN developing_VBG
        FDA-positive_NNP AR_NNP and_CC MR_NNP after_IN correcting_VBG for_IN two_CD major_JJ
        sources_NNS of_IN bias_NN ._. Accordingly_RB ,_, our_PRP$ estimates_NNS of_IN relative_JJ
        risk_NN associated_VBN with_IN fenfluramine_NN or_CC dexfenfluramine_NN use_NN ,_,
        19_CD ._. 6_CD for_IN AR_NNP and_CC 5_CD ._. 9_CD for_IN MR_NNP ,_, are_VBP higher_JJR than_IN in_IN prior_JJ
        reviews_VBZ ._. These_DT findings_NNS lend_VBP strong_JJ support_NN to_TO the_DT view_NN
        that_DT fenfluramine_NN and_CC dexfenfluramine_NN are_VBP potent_JJ causal_NN
        factors_NNS in_IN the_DT development_NN of_IN both_DT aortic_JJ and_CC mitral_NN
        valvular_NN heart_NN disease_NN ._.
      
      
        Competing_VBG Interests_NNP
        Dr_NNP ._. Hopkins_NNP and_CC Dr_NNP ._. Polukoff_NNP have_VBP been_VBN retained_VBN as_IN
        consultants_NNS for_IN plaintiff_NN attorneys_NNS representing_VBG persons_NNS
        who_WP have_VBP taken_VBN fenfluramine_NN and_CC dexfenfluramine_NN ._.
      
    
  
